Biosurgery refers to the use of biological materials and techniques to aid in surgical procedures and promote wound healing. Biosurgical products are made from materials such as human or animal tissue, collagen, and proteins and are designed to help control bleeding, prevent adhesion formation, and promote tissue regeneration.
The increasing number of surgical procedures stimulates the worldwide market, growing demand for minimally invasive surgeries, and rising incidence of sports-related injuries and trauma cases.
The market for biosurgery in 2021 was worth USD 15.93 billion, and by 2030 it will be worth USD 26.25 billion, at a 5.7% CAGR during the forecast period.
The market includes various products, including fibrin and collagen-based sealants, bone-graft substitutes, and soft tissue patches. These products are used in several surgical procedures, such as orthopedic surgeries, cardiovascular surgeries, and neurosurgeries.
The primary factor propelling the market’s expansion is the rising prevalence of musculoskeletal problems that must be treated surgically. Additionally, the growing senior population, more susceptible to osteoporosis and other chronic medical conditions, is fueling market expansion. Biosurgery is becoming increasingly popular among patients and healthcare professionals as a minimally invasive (MI) alternative to sutures and staples for managing blood loss in patients. Accordingly, the increase in sports-related injuries and unintentional traumas fuels the market’s expansion. A number of technical developments, such as the creation of multipurpose, plasma-based solutions for biosurgeries, are also helping the industry expand.
Market expansion is hampered in developed nations due to the lack of knowledge, a shortage of medical professionals, and a lack of medical infrastructure.
There is rising adoption of cutting-edge biosurgical devices in emerging nations. Emerging market markets are distinguished by a huge patient population for target indications such as (cardiovascular, gynecological, and orthopedic illnesses), expanding health awareness, rising medical tourism, increasing healthcare expenditure, and fast building healthcare infrastructure. Medical procedures in emerging economies are considerably less expensive than in industrialized ones. Government organizations in these regions are also taking steps to assist their particular healthcare systems, which fosters market growth and increases prospects for biosurgery.
In 2022, the hemostatic agents segment had the highest revenue share. Hemostatic drugs are used to control bleeding during surgical procedures, and their increasing demand is due to their efficiency in doing so, which shortens surgery times and improves patient outcomes. Demand for hemostatic agents is drive by an increase in surgical procedures due to the increase frequency of chronic disorders such as diabetes, cancer, and cardiovascular disease.
Due to the increasing prevalence of bone diseases such as osteoporosis, osteoarthritis, and spinal issues, the orthopedic surgery category had the greatest revenue share in 2022. By reducing blood loss, postoperative complications, and recovery time, using biosurgery products in orthopedic surgery helps to mend bones and tissues. Additionally, the rise in sports-related injuries and the rising global elderly population contribute to the orthopedic surgery segment’s revenue growth.
The general surgery segment will have the quickest revenue CAGR. The general surgery segment’s revenue growth is drive by the rising incidence of chronic diseases, including cancer and gastrointestinal disorders, and the growing demand for less invasive procedures.
In 2021, the hospital sector accounted for the largest share of the biosurgery market. In contrast to other end-use segments, hospitals are performing a large number of general and gynecological surgery. The development of modern biosurgery treatment modalities and the growth of multispecialty institutions have stimulated the market for biosurgery.
North America was the largest regional market in 2022, with a significant revenue share. The region’s growth is drive by the growing incidence of chronic illnesses like cancer and diabetes and the increase usage of innovative surgical techniques. Additionally, well-developed healthcare infrastructure and favorable reimbursement policies are stimulating market expansion in this region.
The Asia Pacific market will have the fastest revenue growth. The market is expanding due to an aging population and growing healthcare expenditures. The demand for products use in biosurgery is also drive by the fact that many more procedures are being perform in the area. Furthermore, the market in the area is growing due to expanding medical tourism and more affordable biosurgery products.
- Becton, Dickinson & Co.
- B. Braun Melsungen AG
- Baxter International Inc.
- Johnson & Johnson
- Medtronic Plc
- Integra Lifesciences Holdings Corp.
- CSL Ltd.
- Stryker Corp.
- Hemostasis L.L.C.
- Zimmer Biomet
- Pfizer Inc.
- Cyrolife Inc.
- Kuros Biosciences AG
- ecm biosurgery
- Orthofix Medical Inc.
- Smiths & Nephew Plc.
- Genzyme biosurgery
The market for biosurgery in 2021 was worth USD 15.93 billion. And by 2030 it will be worth USD 26.25 billion, at a 5.7% CAGR during the forecast period. The growing elderly population and rising number of operations are contributing to the considerable growth of the global biosurgery market.
Property Management Software Market Report – The global property management software market size was $1.64 Billion in 2021. And is predict to reach $2.70 Billion by 2030, representing a CAGR of 5.73% throughout the estimate Forecast period 2021-2030.